Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

acteria, including MRSA.

"Cubist has a proven track record and well established relations with all stakeholders involved in the antibiotics space.  We believe this collaboration will maximize the impact of and de-risk DIFICID's U.S. commercial launch, assuming approval," said Pedro Lichtinger, President and CEO of Optimer.  "Optimer plans to hire 100 sales representatives to target the 1,100 hospitals, which comprise about 70% of U.S. hospital CDI cases.  We also believe this collaboration with Cubist will allow us to accelerate formulary adoption, expand our market reach and penetration to up to 2,000 hospitals, comprising over 90% of U.S. hospital CDI cases, and commit resources to long-term care facilities that comprise approximately one-third of all CDI cases.  In addition, this provides the opportunity to capture the undiagnosed CDI market segment which some estimate to be as many as three million cases per year."

Cubist's President and CEO Michael Bonney said, "We believe that the strengths of Cubist's seasoned sales force, medical affairs team and our experience in the hospital will add tremendous value to Optimer's launch strategy and execution. We look forward to working with Optimer to introduce a much needed therapy for seriously ill patients suffering from CDAD."

The agreement expires two years from the first commercial sale of DIFICID.  The agreement can be renewed for additional terms upon agreement of the parties and can be terminated early by either party in certain defined situations. Optimer will be responsible for the manufacturing and distribution of DIFICID in the United States and for recording product revenue.  Optimer will be responsible for obtaining FDA approval, and will retain ownership of the New Drug Application.  For its efforts under the co-promotion agreement, including providing specified levels of resources and activities, Cubist will receive quarterly service fees of $3.75 mi
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  El Camino Hospital, a ... care, is utilizing the Leaf Patient Monitoring system to ... and movement of patients susceptible to bed sores. ... month-long, 138-patient study of the system, which showed dramatic ... Turning patients regularly is the one of the most ...
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
(Date:7/30/2014)... 30, 2014 Cynosure, Inc. (NASDAQ: ... treatments for non-invasive and minimally invasive applications, today announced that ... Operating Officer and Chief Financial Officer Timothy W. Baker ... Baker, 53, will continue to serve as CFO and will ... who remains Chairman and Chief Executive Officer. ...
Breaking Medicine Technology:El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, 2014 ... least 2,000 Americans die from extreme heat or cold, floods ... stroke or sun stroke caused nearly one-third of more than ... the U.S. Centers for Disease Control and Prevention. Cold ... -- accounted for 63 percent of those weather-related deaths. The ...
(Date:7/30/2014)... SF Cable, distributor of the highest quality cables, ... internet with guaranteed customer satisfaction announces the availability of ... These lightning cords are MFI certified to meet Apple ... Cable Lightning to USB Cables feature the ... and syncing. Compatible with the iPhone 5S/5C/5 plus iPad ...
(Date:7/30/2014)... 30, 2014 Visitors to our region ... $8,500 to ensure its protection. Bob Kiesendahl, one of ... to the Delaware Highlands Conservancy for donations collected through ... $2-per-stay donations add up fast, as visitors welcome the ... Delaware River Region. , The Kiesendahl family has owned ...
(Date:7/30/2014)... DRE Medical — a leading medical equipment ... its Medical Trade Shows & Conventions Calendar Schedule ... equipment vendors. , The calendar is a continually-updating guide ... States and around the world. Hundreds of entries are ... always growing. , Information listed on each trade show ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... Ensign Group, Inc. (Nasdaq: ENSG ), the parent company of the Ensign™ ... that its Board of Directors has declared a quarterly cash dividend of ... April 30, 2010 to shareholders of record as of March 31, ... ...
... March 15 Centocor Ortho Biotech Products has informed PharmaMar SA (Grupo Zeltia, ... have approved Yondelis(R) for advanced soft tissue sarcoma (STS) in adults. Furthermore, the authorities ... ovarian cancer (ROC). Yondelis is already approved for STS in Paraguay and ... ...
... Spotlighting the importance of oral health care for expectant mothers, the California Dental Association (CDA) Foundation has released new guidelines designed to emphasize the safety of dental treatment during ... ... ... ...
... at the University of Minnesota Medical School have discovered ... the hearts of Duchenne muscular dystrophy patients a ... children. The chemical, which Medical School scientists have termed ... heart muscle. When injected into the bloodstream, the molecular ...
... aspects of March Madness, offer tips to temper drawbacks , ... , , ... ... CHICAGO , March 15 ...
... ON , March 15 /PRNewswire-FirstCall/ - Nuvo Research ... the research and development of drug products that are delivered ... drug delivery technologies, and on the development of its immune ... the first patient in its European Phase 2 clinical trial ...
Cached Medicine News:Health News:The Ensign Group Declares Quarterly Dividend 2Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 2Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 3Health News:Yondelis(R) Receives Five New Approvals Outside the European Economic Area 4Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 2Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 3Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 4Health News:Researchers discover chemical that may protect hearts of muscular dystrophy patients 2Health News:Experts Say It's Not So Bad to Go a Little Mad 2Health News:Experts Say It's Not So Bad to Go a Little Mad 3Health News:Experts Say It's Not So Bad to Go a Little Mad 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 2Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 3Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 4Health News:Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial 5
Lyphochek Coagulation Control is a human plasma control for monitoring the performance of routine coagulation tests. It has an extended reconstituted stability which helps reduce waste and save money...
Lyphochek® Hemoglobin A1C Linearity Set is a human whole blood based product designed to verify linearity throughout the patient reportable range of hemoglobin A1C assays....
... Hematology-16 Control is specifically ... most hematology analyzers that ... parameters and 3-part white ... trilevel control can be ...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: